AK129 Combination Therapy for Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Akeso
Treatments:
Carboplatin Cetuximab Cisplatin Docetaxel Drug Therapy Fluorouracil Paclitaxel Pemetrexed penpulimab